U.S. market Closed. Opens in 11 hours 56 minutes

CYCC | Cyclacel Pharmaceuticals, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-312001-12-312000-12-31
Revenue420.00KN/AN/AN/AN/A150.00KN/A843.00K1.94M1.73M1.08M69.00K699.00K686.00K911.00K877.00K129.00K387.00K813.00K62.00K170.00KN/A30.00K98.00K
Cost of Revenue31.00K32.00K43.00K20.00K20.00KN/AN/AN/AN/AN/AN/AN/A360.00K418.00K545.00K429.00K19.57M21.20MN/AN/AN/AN/AN/AN/A
Gross Profit389.00K-32.00K-43.00K-20.00K-20.00K150.00KN/AN/A1.94M1.73M1.08M69.00K339.00K268.00K366.00K448.00K-19.44M-20.82M813.00K62.00K170.00KN/AN/AN/A
Operating Expenses30.69M27.66M22.94M10.64M9.68M9.70M9.49M14.99M18.11M24.17M19.06M15.17M16.73M16.53M18.30M34.22M11.54M12.32M30.50M26.57M18.01MN/A19.91M13.66M
Selling, General & Admin6.72M7.38M7.46M5.88M5.02M5.37M5.25M5.52M5.73M5.89M7.78M8.58M7.52M10.12M8.54M15.35M11.54M12.32M9.67M6.88M4.32MN/A5.20M2.40M
Research & Development23.97M20.27M15.48M4.76M4.66M4.33M4.24M9.48M12.38M18.28M11.28M6.59M9.21M6.41M9.77M18.87MN/AN/A13.77M19.70M13.69M14.66M14.70M11.26M
Other Operating Expenses50.00K1.30M144.00K891.00K231.00K682.00KN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A7.06MN/AN/AN/AN/AN/A
Operating Income-30.30M-27.66M-22.94M-10.64M-9.68M-9.55M-9.49M-14.15M-16.17M-22.44M-17.97M-15.10M-16.39M-16.27M-17.94M-33.77M-30.98M-33.14M-29.69M-26.51M-17.84M-19.64M-19.88M-13.56M
Other Expenses / Income-98.00K1.74M204.00K955.00K556.00K592.00K1.03M376.00K-316.00K-212.00K6.09M-4.00K580.00K-412.00K-2.58M-8.36M4.89M1.63M-7.40M-727.00K-1.00KN/AN/A621.00K
Before Tax Income-30.40M-25.91M-22.73M-9.68M-9.12M-8.62M-8.46M-13.77M-16.49M-22.65M-11.88M-15.11M-15.81M-16.68M-20.52M-42.13M-26.09M-31.50MN/AN/AN/AN/AN/AN/A
Income Tax Expenses-7.84M-4.72M-3.85M-1.24M-1.30M-1.34M-993.00K-1.98M-2.14M-3.24M-1.67M-1.35M-565.00K-657.00K-948.00K-1.75M-2.04M-2.25MN/AN/AN/AN/AN/AN/A
Net Income-22.55M-21.20M-18.89M-8.45M-7.83M-7.29M-7.47M-11.79M-14.34M-19.39M-10.15M-13.19M-15.24M-16.02M-19.57M-40.39M-24.05M-29.26M-29.42M-39.59M-18.46M-19.45M-19.51M-12.94M
Interest ExpensesN/A-2.01MN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A43.00K177.00K318.00KN/AN/AN/AN/AN/AN/AN/AN/A
Basic Shares Outstanding850.82K657.62K595.08K242.22K54.41K604.71K381.56K171.25K135.65K91.48K63.16K29.94K29.94K22.53K13.21K12.16K11.83K7.97K11.70K7.40K8.79K3.96K3.96K3.96K
Diluted Shares Outstanding850.82K657.62K595.08K242.22K54.41K604.71K381.56K171.25K135.65K91.48K63.16K29.94K29.94K22.53K13.21K12.16K11.83K7.97K11.70K7.40K8.79K4.62K4.62K4.62K
EBITDA-30.27M-27.89M-22.98M-10.66M-9.78M-9.46M-8.43M-13.64M-16.28M-22.46M-11.75M-14.48M-15.57M-16.18M-19.67M-39.95M-25.80M-30.41M-27.87M-38.28M-17.53M-19.64M-19.51M-12.94M
EBITDA Margin-7,206.67%0.00%0.00%0.00%0.00%-6,305.33%0.00%-1,618.15%-837.24%-1,295.04%-1,084.23%-20,981.16%-2,227.04%-2,358.31%-2,159.50%-4,555.87%-19,996.12%-7,857.36%-3,427.80%-61,745.16%-10,310.59%0.00%-65,040.00%-13,205.10%
EBIT-30.40M-27.92M-22.73M-9.68M-9.12M-8.62M-8.46M-13.77M-16.49M-22.63M-11.82M-14.54M-15.81M-16.64M-20.34M-41.82M-26.09M-31.50M-29.42M-39.59M-18.46M-19.45M-19.51M-12.94M
EBIT Margin-7,237.38%0.00%0.00%0.00%0.00%-5,750.00%0.00%-1,633.93%-848.05%-1,305.07%-1,090.68%-21,068.12%-2,261.52%-2,424.93%-2,232.82%-4,768.19%-20,227.91%-8,140.31%-3,618.20%-63,851.61%-10,857.06%0.00%-65,040.00%-13,205.10%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-312001-12-312000-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙